Zambon Biotech SA
June 23, 2026
Theater 4
Type: Company Presentation
Focus Area:
Brain Health
Zambon Biotech is focused in growing the specialty portfolio and pipeline of the Zambon group of companies by entering into partnerships, acquiring assets and supporting their clinical development up to commercialization as well as licensing commercial stage assets.
Zambon Biotech is currently looking to expand our product portfolio and pipeline with opportunities from phase III to Registration, as well as approved products in Central Nervous System and Rare diseases. It leverages the commercial capabilities of Zambon Pharmaceuticals with 23 subsidiaries in Europe, South America and Asia and manufacturing sites in Italy, Switzerland, China and Brazil. Our strategic therapeutic areas for growth are Central Nervous System, Severe Respiratory and Rare diseases. In 2024 the Zambon Group turnover was €885 million with an EBITDA of €192 million and close to 3000 employees.
Company HQ City:
Cadempino
Company HQ State:
Ticino
Company HQ Country:
Switzerland
Year Founded:
1906
Lead Product in Development:
Zambon group has several products being commercialised. Zambon Biotech licensed a post phase III product and is moving forward with regulatory activities. the product is for Parkinson's disease
CEO
Zambon Biotech CEO F.Weber; Zambon Pharma CEO G.Magnaghi
Development Phase of Lead Product
Multiple Products in Market
When you expect your next catalyst update?
Not applicable (see above)
Primary Speaker
.jpg/fit-in/500x9999/filters:no_upscale())
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}